Amgen (AMGN) Goes to Battle Over Knock-Off Biotech Drugs (RHHBY)
Get Alerts AMGN Hot Sheet
Price: $284.32 -0.69%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3.2%
EPS Growth %: +0.3%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3.2%
EPS Growth %: +0.3%
Join SI Premium – FREE
Amgen (Nasdaq: AMGN) shares are higher on the session amid reports that it, along with Roche's (OTCBB: RHHBY) Genentech, is lobbying Washington and multiple states to prevent smaller biotech from producing biosimilar forms of some of its blockbuster drugs.
The two are proposing bills which limit what pharmacists can substitute for brand name products. Proposals have been submitted in eight states this month, the NY Times noted today.
Support seems to be growing, with Virginia's House of Delegates passing one of the bills by a measure of 91 to six.
It's not all about profit though; the companies avow that knock-off forms of the brand name drugs aren't exactly the same, which is why they're called biosimilars rather than generics.
Biosimiar's aren't currently available in the U.S. market, though they have been available in Europe for a number of years. The ongoing battle between the two sides has diminished enthusiasm for companies to enter the biosimilar market, according to the Times. No timeline on when biosimilar makers will be able to sell in the U.S. was given.
Amgen is up 2 percent on the session, while Roche is modestly higher.
The two are proposing bills which limit what pharmacists can substitute for brand name products. Proposals have been submitted in eight states this month, the NY Times noted today.
Support seems to be growing, with Virginia's House of Delegates passing one of the bills by a measure of 91 to six.
It's not all about profit though; the companies avow that knock-off forms of the brand name drugs aren't exactly the same, which is why they're called biosimilars rather than generics.
Biosimiar's aren't currently available in the U.S. market, though they have been available in Europe for a number of years. The ongoing battle between the two sides has diminished enthusiasm for companies to enter the biosimilar market, according to the Times. No timeline on when biosimilar makers will be able to sell in the U.S. was given.
Amgen is up 2 percent on the session, while Roche is modestly higher.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Resumes Amgen (AMGN) at Market Perform
- Aldeyra Therapeutics (ALDX) Lays Out Clinical Development Plan for Resubmission of NDA for Reproxalap in Dry Eye Disease
- 89bio Inc. (ETNB) Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!